INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experience

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/8520

Files in this item

File Description Format
PDF LMWH Pregnancy ... rmacotherapy revisions.pdf (117KB) (no description provided) PDF
Title: Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experience
Author(s): Shapiro, Nancy L.; Kominiarek, Michelle A.; Nutescu, Edith A.; Chevalier, Aimee B.; Hibbard, Judith U.
Subject(s): pregnancy Low-Molecular-Weight Heparin
Abstract: Study Objective. To evaluate dosing requirements and monitoring patterns of low-molecular-weight heparin (LMWH) when used in high-risk pregnancy. Design. Retrospective, observational, cohort study. Setting. University-affiliated medical center. Patients. Forty-nine women treated with LMWH between 2001 and 2005 for either prophylaxis or treatment of venous thromboembolism during pregnancy and monitored with antifactor Xa activity. Measurements and Main Results. Data were obtained on 53 pregnancies in the 49 women. The primary outcome was change in dosing requirements of LMWH throughout pregnancy as determined by the corresponding antifactor Xa activity peak levels. Mean starting doses of twice-daily enoxaparin and doses most proximate to delivery were 39.2 mg (range 30– 60 mg) and 55.0 mg (range 30–100 mg, p=0.06), respectively, for the prophylaxis group and 83.0 mg (range 30–180 mg) and 85.7 mg (range 30–160 mg, p=0.41), respectively, for the therapeutic group. Weight-based mean starting doses and doses most proximate to delivery were 0.46 and 0.62 mg/kg (p=0.03), respectively, for the prophylaxis group and 0.90 and 0.87 mg/kg (p=0.29), respectively, for the therapeutic group. Dose changes were required in 9 (69%) of 13 pregnancies and 21 (55%) of 38 pregnancies (data from two of the 40 pregnancies were excluded—one in a patient receiving dalteparin, and one in a patient with mitral valve replacement who had higher antifactor Xa goals) in the prophylaxis and therapeutic groups, respectively, to achieve target antifactor Xa activity. The weight-based prophylactic dose was consistently 0.6 mg/kg in all three trimesters, achieving a mean ± SD target antifactor Xa activity of 0.39 ± 0.18 units/ml, whereas the therapeutic dose was 0.9 mg/kg to maintain antifactor Xa activity of 0.71 ± 0.22 units/ml. Conclusion. Dose changes for LMWH throughout pregnancy as guided by antifactor Xa activity were common. A significant increase in the LMWH dose requirements in the prophylactic group suggests that more frequent monitoring of antifactor Xa activity may be appropriate in pregnant patients to maintain target anticoagulant levels.
Issue Date: 2011-07
Publisher: IOS Press
Citation Info: Shapiro, N. L., Kominiarek, M. A., Nutescu, E. A., Chevalier, A. B., & Hibbard, J. U. 2011. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experience. Pharmacotherapy, 31(7): 678-685. DOI: 10.1592/phco.31.7.678.
Type: Article
Description: © 2011 by IOS Press, Pharmacotherapy Post print version of article may differ from published version. The definitive version is available through IOS Press at DOI: 10.1592/phco.31.7.678.
URI: http://hdl.handle.net/10027/8520
ISSN: 0277-0008
Date Available in INDIGO: 2012-08-17
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 136
China 35
United Kingdom 11
Germany 4
France 2

Browse

My Account

Information

Access Key